Search

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US

Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

New consortium EUbOPEN will provide tools to unlock disease biolog

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Financial year 2018

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

Social Impact | COVID-19 | Boehringer Ingelheim US

Click to find out more on how Boehringer Ingelheim (BI) is standing together with our communities to support the fight against the COVID-19 pandemic.

Words of Health and Hope

Click here to hear from our patients, who have expressed to us in beautifully written thank you notes for our BI Cares Patient Assistance Program.

Jardiance® (empagliflozin) Tablets Reduce Risk of CV Death | Boehringer Ingelheim US

EMPA-REG OUTCOME® trial: New analyses show that JARDIANCE reduced the risk of CV death in adults with T2D. View ISI, PI and Med Guide.

Boehringer Ingelheim and Lilly Welcome New Recommendation for Jardiance® (empagliflozin) tablets in Updated American Diabetes Association’s 2017 Standards

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

New Analyses Showed Consistent Efficacy of OFEV® (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis (IPF)

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers